TY - JOUR
T1 - Predictive factors, management, and clinical outcomes of coronary obstruction following transcatheter aortic valve implantation
T2 - Insights from a large multicenter registry
AU - Ribeiro, Henrique B.
AU - Webb, John G.
AU - Makkar, Raj R.
AU - Cohen, Mauricio G.
AU - Kapadia, Samir R.
AU - Kodali, Susheel
AU - Tamburino, Corrado
AU - Barbanti, Marco
AU - Chakravarty, Tarun
AU - Jilaihawi, Hasan
AU - Paradis, Jean Michel
AU - De Brito, Fabio S.
AU - Cánovas, Sergio J.
AU - Cheema, Asim N.
AU - De Jaegere, Peter P.
AU - Del Valle, Raquel
AU - Chiam, Paul T.L.
AU - Moreno, Raúl
AU - Pradas, Gonzalo
AU - Ruel, Marc
AU - Salgado-Fernández, Jorge
AU - Sarmento-Leite, Rogerio
AU - Toeg, Hadi D.
AU - Velianou, James L.
AU - Zajarias, Alan
AU - Babaliaros, Vasilis
AU - Cura, Fernando
AU - Dager, Antonio E.
AU - Manoharan, Ganesh
AU - Lerakis, Stamatios
AU - Pichard, Augusto D.
AU - Radhakrishnan, Sam
AU - Perin, Marco Antonio
AU - Dumont, Eric
AU - Larose, Eric
AU - Pasian, Sergio G.
AU - Nombela-Franco, Luis
AU - Urena, Marina
AU - Tuzcu, E. Murat
AU - Leon, Martin B.
AU - Amat-Santos, Ignacio J.
AU - Leipsic, Jonathon
AU - Rodés-Cabau, Josep
N1 - Funding Information:
Dr. Ribeiro has received funding via a research grant from the Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brasil . Dr. Webb has received consulting fees from Edwards Lifesciences and St. Jude Medical. Dr. Makkar has received research grants from Edwards Lifesciences , Medtronic , Abbott , Capricor , and St. Jude Medical ; has served as a proctor for Edwards Lifesciences; and has received consulting fees from Medtronic. Dr. Cohen has served on the Speakers' Bureau of Medtronic; and has received consulting fees from Edwards Lifesciences and St. Jude Medical. Dr. Kodali has received consulting fees from Edwards Lifesciences; has served on the steering committees of Edwards Lifesciences and St. Jude Medical; has served on the Speakers' Bureau of Thubrikar Aortic Valve, Inc.; and has equity in Thubrikar Aortic Valve. Dr. Tamburino has received support from Edwards Lifesciences , Abbott , and CardioKinetix ; and has a speaking honorarium with CardioKinetix. Dr. Jilaihawi has received consulting fees from Edwards Lifesciences, St. Jude Medical, and Venus Medtech. Dr. de Brito has received honoraria from Medtronic and Edwards Lifesciences for symposium speeches and proctoring cases. Dr. de Jaegere has received consulting fees from Medtronic. Dr. Chiam has served as a proctor for Edwards Lifesciences and has received consulting fees from Medtronic. Dr. Ruel has served as a proctor for and has received consulting fees from Medtronic. Dr. Sarmento-Leite has served as a proctor for and has received consulting fees from Medtronic. Dr. Velianou has served as a proctor for and received consulting fees from Edwards Lifesciences. Dr. Zajarias has received consulting fees from Edwards Lifesciences and has served on the steering committee of the PARTNER 2 trial. Dr. Babaliaros has served as an investigator for Edwards Lifesciences and has received consulting fees from Direct Flow Medical. Dr. Dager has received proctoring honoraria from Medtronic. Dr. Manoharan has received consulting fees from St. Jude Medical. Dr. Lerakis has received consulting fees from Edwards Lifesciences. Dr. Pichard has received consulting fees from and has served as a proctor for Edwards Lifesciences. Dr. Radhakrishnan has received consulting fees from and has served as a proctor for Medtronic. Dr. Perin has received consulting fees from Medtronic. Dr. Dumont has received consulting fees from Edwards Lifesciences. Dr. Leon has received research grants for clinical trials from Edwards Lifesciences . Dr. Amat-Santos was supported by the Instituto de Salud Carlos III (Madrid, Spain) through a contract “Río Hortega” at the ICICOR . Dr. Leipsic has received consulting fees from and has served on the Speakers' Bureau of Edwards Lifesciences. Dr. Rodés-Cabau has received consulting fees from Edwards Lifesciences and St. Jude Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2013/10/22
Y1 - 2013/10/22
N2 - Objectives This study sought to evaluate the main baseline and procedural characteristics, management, and clinical outcomes of patients from a large cohort of patients undergoing transcatheter aortic valve implantation (TAVI) who suffered coronary obstruction (CO). Background Very little data exist on CO following TAVI. Methods This multicenter registry included 44 patients who suffered symptomatic CO following TAVI of 6,688 patients (0.66%). Pre-TAVI computed tomography data was available in 28 CO patients and in a control group of 345 patients (comparisons were performed including all patients and a cohort matched 1:1 by age, sex, previous coronary artery bypass graft, transcatheter valve type, and size). Results Baseline and procedural variables associated with CO were older age (p < 0.001), female sex (p < 0.001), no previous coronary artery bypass graft (p = 0.043), the use of a balloon-expandable valve (p = 0.023), and previous surgical aortic bioprosthesis (p = 0.045). The left coronary artery was the most commonly involved (88.6%). The mean left coronary artery ostia height and sinus of Valsalva diameters were lower in patients with obstruction than in control subjects (10.6 ± 2.1 mm vs. 13.4 ± 2.1 mm, p < 0.001; 28.1 ± 3.8 mm vs. 31.9 ± 4.1 mm, p < 0.001). Differences between groups remained significant after the case-matched analysis (p < 0.001 for coronary height; p = 0.01 for sinus of Valsalva diameter). Most patients presented with persistent severe hypotension (68.2%) and electrocardiographic changes (56.8%). Percutaneous coronary intervention was attempted in 75% of the cases and was successful in 81.8%. Thirty-day mortality was 40.9%. After a median follow-up of 12 (2 to 18) months, the cumulative mortality rate was 45.5%, and there were no cases of stent thrombosis or reintervention. Conclusions Symptomatic CO following TAVI was a rare but life-threatening complication that occurred more frequently in women, in patients receiving a balloon-expandable valve, and in those with a previous surgical bioprosthesis. Lower-lying coronary ostium and shallow sinus of Valsalva were associated anatomic factors, and despite successful treatment, acute and late mortality remained very high, highlighting the importance of anticipating and preventing the occurrence of this complication.
AB - Objectives This study sought to evaluate the main baseline and procedural characteristics, management, and clinical outcomes of patients from a large cohort of patients undergoing transcatheter aortic valve implantation (TAVI) who suffered coronary obstruction (CO). Background Very little data exist on CO following TAVI. Methods This multicenter registry included 44 patients who suffered symptomatic CO following TAVI of 6,688 patients (0.66%). Pre-TAVI computed tomography data was available in 28 CO patients and in a control group of 345 patients (comparisons were performed including all patients and a cohort matched 1:1 by age, sex, previous coronary artery bypass graft, transcatheter valve type, and size). Results Baseline and procedural variables associated with CO were older age (p < 0.001), female sex (p < 0.001), no previous coronary artery bypass graft (p = 0.043), the use of a balloon-expandable valve (p = 0.023), and previous surgical aortic bioprosthesis (p = 0.045). The left coronary artery was the most commonly involved (88.6%). The mean left coronary artery ostia height and sinus of Valsalva diameters were lower in patients with obstruction than in control subjects (10.6 ± 2.1 mm vs. 13.4 ± 2.1 mm, p < 0.001; 28.1 ± 3.8 mm vs. 31.9 ± 4.1 mm, p < 0.001). Differences between groups remained significant after the case-matched analysis (p < 0.001 for coronary height; p = 0.01 for sinus of Valsalva diameter). Most patients presented with persistent severe hypotension (68.2%) and electrocardiographic changes (56.8%). Percutaneous coronary intervention was attempted in 75% of the cases and was successful in 81.8%. Thirty-day mortality was 40.9%. After a median follow-up of 12 (2 to 18) months, the cumulative mortality rate was 45.5%, and there were no cases of stent thrombosis or reintervention. Conclusions Symptomatic CO following TAVI was a rare but life-threatening complication that occurred more frequently in women, in patients receiving a balloon-expandable valve, and in those with a previous surgical bioprosthesis. Lower-lying coronary ostium and shallow sinus of Valsalva were associated anatomic factors, and despite successful treatment, acute and late mortality remained very high, highlighting the importance of anticipating and preventing the occurrence of this complication.
KW - coronary obstruction
KW - coronary occlusion
KW - percutaneous aortic valve replacement
KW - percutaneous coronary intervention
KW - transcatheter aortic valve implantation
UR - http://www.scopus.com/inward/record.url?scp=84886073216&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2013.07.040
DO - 10.1016/j.jacc.2013.07.040
M3 - Article
C2 - 23954337
AN - SCOPUS:84886073216
SN - 0735-1097
VL - 62
SP - 1552
EP - 1562
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 17
ER -